Screener
Cullinan Therapeutics, Inc. CGEM Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Cullinan Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Cullinan Therapeutics, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:10 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336717
FAQ
- What is Cullinan Therapeutics, Inc.'s cash & equivalents?
- Cullinan Therapeutics, Inc. (CGEM) reported cash & equivalents of $78.64M in Q2 2026.
- How has Cullinan Therapeutics, Inc.'s cash & equivalents changed year-over-year?
- Cullinan Therapeutics, Inc.'s cash & equivalents increased by 8.0% year-over-year, from $72.82M to $78.64M.
- What is the long-term trend for Cullinan Therapeutics, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Cullinan Therapeutics, Inc.'s cash & equivalents has grown at a -12.1% compound annual growth rate (CAGR), from $168.2M to $88.33M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Cullinan Therapeutics, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude